RT Journal Article
SR Electronic
T1 The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.04.22270433
DO 10.1101/2022.02.04.22270433
A1 Hassan, Shermarke
A1 Ferrari, Barbara
A1 Rossio, Raffaella
A1 la Mura, Vincenzo
A1 Artoni, Andrea
A1 Gualtierotti, Roberta
A1 Martinelli, Ida
A1 Nobili, Alessandro
A1 Bandera, Alessandra
A1 Gori, Andrea
A1 Blasi, Francesco
A1 Monzani, Valter
A1 Costantino, Giorgio
A1 Harari, Sergio
A1 Rosendaal, Frits R.
A1 Peyvandi, Flora
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270433.abstract
AB Background The coronavirus disease 2019 (COVID-19) presents an urgent threat to global health. Identification of predictors of poor outcomes will assist medical staff in treatment and allocating limited healthcare resources.Aims The primary aim was to study the value of D-dimer as a predictive marker for in-hospital mortality.Methods This was a cohort study. The study population consisted of hospitalized patients (age >18 years), who were diagnosed with COVID-19 based on real-time PCR at 9 hospitals during the first COVID-19 wave in Lombardy, Italy (Feb-May 2020). The primary endpoint was in-hospital mortality. Information was obtained from patient records. Statistical analyses were performed using a Fine-Gray competing risk survival model. Model discrimination was assessed using Harrell’s C-index and model calibration was assessed using a calibration plot.Results Out of 1049 patients, 501 patients had evaluable data. Of these 501 patients, 96 died. The cumulative incidence of in-hospital mortality within 30 days was 20% (95CI: 16%-23%), and the majority of deaths occurred within the first 10 days. A prediction model containing D-dimer as the only predictor had a C-index of 0.66 (95%CI: 0.61-0.71). Overall calibration of the model was very poor. The addition of D-dimer to a model containing age, sex and co-morbidities as predictors did not lead to any meaningful improvement in either the C-index or the calibration plot.Conclusion The predictive value of D-dimer alone was moderate, and the addition of D-dimer to a simple model containing basic clinical characteristics did not lead to any improvement in model performance.Competing Interest StatementB. Ferrari has received consulting fees and travel support from Sanofi Genzyme. R. Gualtierotti reports participation in advisory boards for Biomarin, Pfizer, Bayer and Takeda as well as participation at educational seminars sponsored by Pfizer, Sobi and Roche. I. Martinelli reports personal and non-financial support from Bayer, Roche, Rovi and Novo Nordisk outside of the submitted work. A. Gori has received grants for research support, honoraria, consultation fees, and travel support from Gilead, Janssen, MSD, Pfizer, Angelini, Menarini, ViiV. F. Peyvandi has received honoraria for participating as a speaker at educational meetings, symposia and advisory boards of Roche, Sobi, Sanofi, Grifols and Takeda. All other authors have no conflicts of interest to disclose.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical Ethics Committee of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor original data, please contact the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre (emostasitrombosi{at}policlinico.mi.it).